$150,000 KeyBank Gift Supports Teen Mental Health and Wellness Throughout Hudson Valley
'Everyone needs a little help from time to time, especially the youth in our communities,' said John Manginelli, Hudson Valley/Metro NY President, KeyBank. 'To support this program with Family Services, which provides teens with the resources they need in a way they will be receptive to receiving them, is a great way to promote KeyBank's commitment to help people live well and thrive.'
'KeyBank Foundation is committed to supporting organizations and programs that prepare individuals for thriving futures. Family Services' enhanced youth programming does just this. It is a transformative approach to teen behavioral health that helps kids realize their promise and aligns perfectly with our philanthropic priorities of neighbors, education and workforce,' said Eric Fiala, CEO, KeyBank Foundation.
According to a 2023 article by the US Center for Disease Control, in the 10 years leading up to the pandemic, feelings of persistent sadness and hopelessness in young people—as well as suicidal thoughts and behaviors—increased approximately 40% percent. In the Hudson Valley, the percentage of children with serious emotional disability grew from 15% to 38%.
Additionally, the City of Poughkeepsie continues to face gun violence; in 2024,16 people were shot, 6 of whom were teenagers. When youth face exposure to trauma such as community violence and other adverse childhood experiences, it can lead to significant behavioral health needs, poor social outcomes, health disparities and educational deficiencies if left unaddressed.
'At Family Services our north star is ensuring everyone has the right to thrive. For the youth we serve, that includes meeting increasing behavioral health needs,' said Leah Feldman, CEO, Family Services. 'We're grateful for KeyBank's continued support and commitment to help us deliver on our reimagined model for improving mental health outcomes for teens so they can reach their fullest potential.'
Family Services is planning to welcome their first participants in the summer of 2025.
Recruitment for the new program will occur in several ways, including outreach to youth and parents involved in Family Services' Teen Resource Activity Center programming, referrals from Poughkeepsie City School District, referrals from Family Services partner agencies within the Poughkeepsie Children's Cabinet and community outreach.
For more information, visit the Family Services website at http://familyservicesny.org or call 845-452-1110 x3192.
Visit 3BL Media to see more multimedia and stories from KeyBank
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Jelly Roll's Wife Shares Honest Thoughts on His Dramatic Weight-Loss Transformation
Jelly Roll's Wife Shares Honest Thoughts on His Dramatic Weight-Loss Transformation originally appeared on Men's Fitness. Jelly Roll's wife prefers him on the squishy side. Jelly Roll's wife, Alyssa DeFord—known online as Bunnie XO—playfully poked fun at her trimmed-down husband on TikTok. "When you have to check and make sure he's still your squish after all the weight loss," she wrote, referencing Jelly Roll's impressive weight loss. The clip shows Jelly Roll leaning against a rock wall as Bunnie stood in front of him. She lunged forward, slamming her chest against his, prompting a surprised look from Jelly Roll before he joked with her to do it again. After the second slam, Jelly Roll showed a playful look of pain before pulling Bunnie into an embrace. The couple tied the knot in 2016 and renewed their vows in 2023. While their love has stayed strong, Jelly Roll's appearance has significantly changed since they married nearly a decade ago. His weight-loss journey has been public, with updates shared periodically on his progress. At his heaviest, he weighed over 500 pounds, but he's committed to a lifestyle recently, he revealed he was about to drop below 300 pounds for the first time since middle school. As he checks off his weight-loss milestones, Jelly Roll has his sights set on reaching 250 pounds and eventually doing a shirtless magazine cover. "For the non-fluffy people in the world, I would give y'all some educational course here—to do all the fun stuff in life, you've got to be under 250. I want to skydive, I want to ride a roller coaster. I want to ride a bull," Jelly Roll said on an episode of Jimmy Kimmel Live earlier this Roll's Wife Shares Honest Thoughts on His Dramatic Weight-Loss Transformation first appeared on Men's Fitness on Aug 19, 2025 This story was originally reported by Men's Fitness on Aug 19, 2025, where it first appeared. Solve the daily Crossword
Yahoo
19 minutes ago
- Yahoo
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential businesses, today announced that its Board of Directors has approved a reduction of the Company's authorized shares of common stock from 350 million to 300 million. This strategic reduction in authorized shares of common stock is a direct reflection of the Board's confidence in the Company's current trajectory and its commitment to protecting long-term shareholder value. "This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are confident in our financial health, strategic plan, and we are committed to preventing unnecessary shareholder dilution.' With the Company's outstanding share count at approximately 294.3 million, the Board determined that the previous authorization level of 350 million shares was no longer necessary given the Company's direction and financial planning. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. In addition, the company has recently expanded into the premium American-made BBQ tool brand market through the acquisition of BBQraft. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684IR@
Yahoo
19 minutes ago
- Yahoo
Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ('Vivos' or the 'Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the three and six months ended June 30, 2025. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated, 'The second quarter of 2025 was a particularly important one in the history of Vivos. Building on our initiatives from 2024, we completed the key acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada. This acquisition marked a pivot in our core sales, marketing, and distribution model from one reliant on dentists alone for subscription and product revenue to a more comprehensive model that allows us to capture both OSA diagnostic and treatment revenue via more direct relationships with the patients who desperately need cutting-edge OSA treatments like ours.' 'This pivot was coupled with our investment in SCN plus a continued weaning off of our legacy enrollment revenue streams, and our weaker comparative second quarter results reflect this,' continued Mr. Huntsman. 'However, we are thrilled with what we are seeing out of SCN, as we recognized approximately $500,000 of diagnostic sleep testing services revenue over just twenty days from the June 10 closing to the end of the quarter.' 'Moreover, demand at SCN locations adapted to our Vivos model so far continues to exceed our current capacity, with patient appointments booked out for weeks and less than 40% of patients currently being served. This validates our belief in our new model, and so we are actively looking to scale this model in the quarters ahead with additional sleep center alliances or acquisitions. So, in sum, we believe we are ably navigating our strategic business model pivot, and we are confident that the future of Vivos is bright and that our strategic initiatives have positioned us for long-term growth,' concluded Mr. Huntsman. Second Quarter 2025 Financial and Operating Summary ● Revenue was $3.8 million for the second quarter of 2025 and $6.8 million for the six months ended June 30, 2025, compared to $4.1 million and $7.5 million for the three and six months ended June 30, 2024. The decline was expected and due to lower product and service revenue, resulting from Vivos' ongoing pivot in its sales, marketing and distribution model to focus on sleep center provider-based alliances and acquisitions, highlighted by Vivos' June 10, 2025 acquisition of SCN, the largest operator of medical sleep centers in Nevada (Vivos Closes SCN Acquisition); ● Gross profit was $2.1 million for the second quarter of 2025 and $3.6 million for the six months ended June 30, 2025, compared to $2.7 million and $4.6 million for the comparable periods in 2024, the decline attributable to the decrease in product and service revenue; ● Gross margin declined to 55% in the second quarter of 2025 from 65% in the second quarter of 2024. For the six months ended June 30, 2025, gross margin was 53% compared to 61% in the same period in 2024. This decrease was expected due to pricing discounts, shifts in product and service mix and the transition to Vivos' new sales, marketing and distribution model; ● Operating expenses for the second quarter ended June 30, 2025 were $7.0 million, a 52% increase compared to $4.6 million in the same period a year ago, reflecting increased spend in general and administrative owing to greater professional fees related to the equity and debt financings required for the acquisition and operation of SCN (much of which is expected to be non-recurring) and personnel and infrastructure costs associated with Vivos' integration of SCN. For the six months ended June 30, 2025, operating expenses were $12.4 million versus $10.3 million in the same period in 2024. ● The second quarter 2025 operating loss increased to $4.9 million compared to $1.9 million in the second quarter of 2024 and increased to $8.8 million for the six months ending June 30, 2025 from $5.7 million for the six months ended June 30, 2024. ● At June 30, 2025, cash and cash equivalents were $4.4 million and stockholders' equity was $4.6 million, compared to cash and equivalents of $6.2 million and stockholders' equity of $8.0 million respectively, as of December 31, 2024. Updated OSA Provider Management Model In addition to growth through acquisitions of medical sleep providers like SCN, Vivos is actively developing an updated sleep practice management model that it is implementing in situations where the sleep center or medical practice owners are not interested in being purchased, but are interested in making the full array of Vivos' OSA diagnostic and treatment options available to their patients. In furtherance of this initiative, on July 14, 2025, Vivos entered into its first such management agreement with MISleep Solutions LLC to provide our full suite of Vivos treatments and services to OSA patients at a joint location in Auburn Hills, Michigan (which is near Detroit). Consistent with its updated approach, Vivos owns a supermajority equity stake in the management services company, with the sleep doctors having minority ownership interests. Facilities to support these operations are currently being remodeled, with an estimated opening date in October 2025. Vivos is exploring similar arrangements in other states. Investor Call and 10-Q Filing Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos' strategic collaborations and their anticipated effect on near-term revenue growth and cash burn. To access Vivos' investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1118815. The replay will be available until September 2, 2025 A live webcast of the conference call can be accessed on Vivos' website at An online archive of the webcast will be available at Vivos' website for 30 days following the call. In addition, further information on Vivos' financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional comments around Vivos' financial performance are provided in the Vivos' Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025, which will be filed with the Securities and Exchange Commission ('SEC'). The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos' website at About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos' devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos' groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children. OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it's closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA. Founded in 2016 and based in Littleton, CO, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to more thoroughly address the complex needs of OSA patients. Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to . For more information, visit Cautionary Note Regarding Forward-Looking Statements This press release and conference call referred to herein, including statements of the Company's management and other parties made in connection therewith, contain 'forward-looking statements' (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as 'may', 'would', 'should', 'expects', 'projects,' 'potential,' 'intends', 'plans', 'believes', 'anticipates', 'hopes', 'estimates', 'goal'. 'aim' and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the actual future impact of the SCN acquisition on Vivos' future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos' marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual results of the initiatives described herein on Vivos' future revenues and results of operations or the anticipated benefits of the Company's new marketing and distribution model described herein may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to successfully integrate SCN's business into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos' products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to acquire additional sleep centers practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (v) market and other conditions that could impact Vivos' business or ability to obtain financing, and (vi) other risk factors described in Vivos' filings with the Securities and Exchange Commission ('SEC'). Vivos' filings can be obtained free of charge on the SEC's website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Media Inquiries: Bradford AmmanChief Financial Officer and Investor Relations Contactinvestors@ -Financial Tables Follow- VIVOS THERAPEUTICS Condensed Consolidated Balance Sheets (In Thousands, Except Per Share Amounts) June 30,2025 December 31,2024 Current assets Cash and cash equivalents $ 4,402 $ 6,260 Accounts receivable, net of allowance of $664 and $390, respectively 1,633 430 Prepaid expenses and other current assets 695 783 Total current assets 6,730 7,473 Long-term assets Goodwill 8,450 2,843 Property and equipment, net 5,129 3,350 Operating lease right-of-use asset 3,244 1,032 Intangible assets, net 2,225 370 Deposits and other 255 216 Total assets $ 26,033 $ 15,284 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,763 $ 1,098 Accrued expenses 2,302 2,234 Current portion of contract liabilities 480 896 Current portion of operating lease liability 654 477 Current portion of financing lease liability 55 - Current portion of debt 157 - Other current liabilities 1,015 273 Total current liabilities 6,426 4,978 Long-term liabilities Contract liabilities, net of current portion 5 97 Employee retention credit liability 2,904 1,220 Operating lease liability, net of current portion 2,814 1,035 Financing lease liability, net of current portion 141 - Debt, net of current portion 7,760 - Other liabilities 1,400 - Total liabilities 21,450 7,330 Commitments and contingencies Stockholders' equity Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding - - Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 7,324,807 shares as of June 30, 2025 and 5,889,520 shares as of December 31, 2024 - - Additional paid-in capital 117,647 112,141 Accumulated deficit (113,064 ) (104,187 ) Total stockholders' equity 4,583 7,954 Total liabilities and stockholders' equity $ 26,033 $ 15,284 VIVOS THERAPEUTICS Condensed Consolidated Statements of Operations(In Thousands, Except Per Share Amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue Product revenue $ 1,885 $ 1,975 $ 3,698 $ 3,650 Service revenue 1,935 2,079 3,137 3,823 Total revenue 3,820 4,054 6,835 7,473 Cost of sales (exclusive of depreciation and amortization shown separately below) 1,710 1,403 3,219 2,885 Gross profit 2,110 2,651 3,616 4,588 Operating expenses General and administrative 6,409 4,122 11,298 9,043 Sales and marketing 260 320 615 973 Depreciation and amortization 306 145 483 291 Total operating expenses 6,975 4,587 12,396 10,307 Operating loss (4,865 ) (1,936 ) (8,780 ) (5,719 ) Non-operating income (expense) Other expense (163 ) (22 ) (170 ) (24 ) Other income 15 28 73 51 Loss before income taxes (5,013 ) (1,930 ) (8,877 ) (5,692 ) Net loss $ (5,013 ) $ (1,930 ) $ (8,877 ) $ (5,692 ) Net loss per share (basic and diluted) $ (0.55 ) $ (0.60 ) $ (1.00 ) $ (2.06 ) Weighted average number of shares of Common Stock outstanding (basic and diluted) 9,087,202 3,228,363 8,842,604 2,768,934
